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ABSTRACT 
Objective: The objectives of the present research was to develop a simple, precise, economical, accurate, reproducible and sensitive method for the 
quantitative estimation of lafutidine in bulk and its pharmaceutical dosage forms by Ultra Violet (UV) absorption spectrophotometry. 
Methods: The method uses 0.1 N HCl, pH 1.20 as a solvent of choice for the quantitative estimation of lafutidine in bulk and its tablets dosage form 
by UV absorption spectrophotometry at a wavelength of 290 nm. The method was validated for parameters like linearity, range, precision, Limit of 
Detection (LOD), Limit of Quantification (LOQ), accuracy, recovery and stability of the analyte. 
Results: Lafutidine exhibited absorbance maxima at 290 nm in 0.1 N HCl, pH 1.20 solvent. The developed method was validated as per the ICH 
validation guidelines. Beer’s law was obeyed in range of 0-30 µg/ml with r2
Conclusion: The developed method was found suitable for the routine quantitative analysis of lafutidinein bulk and pharmaceutical dosage form. It 
was also concluded that developed UV spectrophotometry method was accurate, precise, linear, reproducible, robust and sensitive.  
= 0.9997. The LOD and LOQ values of lafutidine were found to be 0.545 
µg/ml and 1.654 µg/ml respectively. The mean % recovery for the developed method was found to be in the range of 99.25 to 99.45 % respectively 
for the marketed dosage forms. The developed method was also found to be robust. 
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Lafutidine is chemically 2-(furan-2-ylmethylsulfinyl) N-[4-[4-
(piperidin-1-ylmethyl) pyridin-2-yl] oxybut-2-en-1-yl] acetamide as 
shown in fig. 1 [1]. Lafutidine is not official in any pharmacopoeias. It 
is used as an anti-ulcerating agent as it is the new generation H2 
receptor blocker. It is a H2 receptor antagonist and is reported to 
show potent and long lasting antagonisms of histamine H2 receptor-
mediated effect. It is effective agonist the oesophageal lesions 
induced by acid reflux through inhibition of acid secretions [2]. Oral 
administration of lafutidine is safe and effective in reducing oral 
burning symptoms [3]. The earlier studies suggest that therapy with 
lafutidine is effective and well tolerated in patients with Acid Peptic 
Disorders (APDs). It is also useful in those patients who were 
previously not controlled on Proton Pump Inhibitors (PPIs) and first 
generation H2 Receptor antagonist. Histamine is a chemical present 
in mast cells of the body and its release causes the production of acid 
in the stomach. H2
Therefore development and validation of a spectroscopic method for 
estimation in 0.1 N HCl, pH 1.20 (SGF) would be an ideal approach 
for estimation of lafutidine. The literature survey revealed that 
various methods of analysis for lafutidine have been reported which 
include, Liquid Chromatography-Electrospray Ionization-Tandem 
Mass Spectrometry (LC-ESI-MS) [5], High-Performance Liquid 
Chromatography (HPLC) [6], Liquid Chromatography-Mass 
Spectrometry (LC-MS) and Ultra Violet UV Spectrophotometric [7] 
methods. 
-blockers inhibit histamine action and therefore 
reduce gastric secretion or the amount of acid produced. Therefore 
lafutidine can be used as an empiric therapy to treat APDs. Lafutidine 
has a biological half-life (∼2-3hr) with site-specific absorption in the 
upper part of the gastrointestinal tract (GIT) and is also stable in 
gastric pH [4]. Therefore properties of lafutidine make it suitable for 
the development of controlled or convential drug delivery systems 
which release the drug in the gastric contents of stomach thus 
ensuring optimal bioavailability and high therapeutic effects. 
Some of these methods have enough sensitivity to determine lower 
concentrations of drug; however, many of these techniques are defi-
cient in simplicity, cost-effectiveness and accessibility. Out of these, 
UV spectrophotometry or spectroscopy method is featured by its 
speed, simplicity, accuracy and inexpensiveness. An UV 
Spectroscopic method has been reported for lafutidine in 0.1 N HCl, 
pH 1.20 (SFG) solvent and validated according to ICH norms [8].  
 
 
Fig. 1: Structure of lafutidine [1] 
 
MATERIALS AND METHODS  
Instrumentation  
A double beam UV-Visible spectrophotometer1800, Shimadzu, 
software version 2.23 using 1 cm matched quartz cell with a slit 
width of 1 mm was used for all the spectral and absorbance 
measurements. The scanning speed was kept medium. Digital 
weighing balance (Shimadzu analytical balance) was used for 
weighing purpose.  
Reagents and chemicals  
Pure drug sample of lafutidine with % purity 99.60 was supplied by 
Pure Chem Pharmaceutical Pvt. Ltd. Gujarat, India. The sample was 
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used without further purification. Tablet used for analysis was 
Lafudac manufactured by Unichem Laboratory Ltd. Mumbai and 
Laciloc manufactured by Cadila Pharmaceuticals Ltd. containing 
Lafutidine 10 mg per tablet.  
All chemicals and reagents were of analytical grade and double 
distilled water was used throughout the investigation to develop 
spectral characteristics. 
Selection of solvent  
0.1 N HCl, pH 1.20 was selected as a solvent to study spectral 
characteristics of lafutidine. It was prepared according to Indian 
Pharmacopoeia 2014.  
Preparation of standard stock solution  
Accurately weighed 10 mg pure drug sample of lafutidine was 
transferred to 100 ml (100 μg/ml) calibrated volumetric flask, 
dissolved and made up to the mark with 0.1N HCl, pH 1.20. It was 
the stock solution of lafutidine (100 µg/ml) in 0.1 N HCl, pH 1.20. 
By using the stock solution of 100 µg/ml, subsequently dilution was 
carried out by withdrawing different aliquots (0.5, 1.0, 1.5, 2.0, 2.5, 
3.0 ml) from standard solution were transferred into a series of 10 
ml calibrated volumetric flasks and all were made up to the mark 
with 0.1 N HCl, pH 1.20 in order to prepare working standard 
solutions of different concentrations (5-30 µg/ml). 
Selection of detection wavelength 
A solution of lafutidine in the concentration of 10 µg/ml was scanned 
in the range of wavelength 200-400 nm [9]. It was observed that the 
lafutidine showed considerable absorbance at a wavelength of 290 nm. 
The absorption spectrum was found sharp and maximum at 
wavelength of 290 nm, therefore, it was selected as the wavelength for 
detection in 0.1 N HCl, pH 1.20. The study of spectrum revealed that 
lafutidine shows a well-defined λmax
Preparation of calibration curve 
 at 290 nm. 
A solution of lafutidine in 0.1 N HCl, pH 1.20 in different 
concentrations (5, 10, 15, 20, 25 and 30 µg/ml) was taken and the 
absorbance of these solutions was measured against solvent 0.1 N 
HCl, pH 1.20 as blank at a wavelength of 290 nm. A calibration curve 
was plotted from the absorbance values so obtained [10]. From the 
calibration curve, it was found that lafutidine obeys Beer’s law in 
concentrations of 5-30 µg/ml. The optical characteristics are 
summarized in table 1. 
 
Table 1: Calibration curve parameter of lafutidine 
S. No. Concentration (µg/ml) Absorbance±SD(nm) 
1. 0 0 
2. 5 0.106±0.002 
3. 10 0.203±0.002 
4. 15 0.286±0.006 
5. 20 0.385±0.001 
6. 25 0.482±0.003 
7. 30 0.581±0.005 
 
 
Fig. 2: Calibration curve of lafutidine 
 
Preparation of sample solution  
Ten tablets of lafutidine (Lafudac, 10 mg) were weighed accurately 
and powdered finely. An accurately weighed quantity of tablets 
powder equivalent to 100 mg of lafutidine was transferred to a 100 
ml volumetric flask and diluted with 0.1 N HCl, pH 1.20 and the 
content was ultrasonicated for 20 min. The volume was made up to 
the mark with solvent and mixed well. The solutions were further 
filtered using whatman no.1 filter paper to remove any unwanted 
particulate matters. The filtered solutions were further 
appropriately diluted with respective solvent to finally produce 
sample solution of concentration 10 µg/ml for analysis. The amount 
of lafutidine present in the sample solution was determined by using 
the calibration curve of standard drug.  
Method validation 
The method was validated according to ICH Q2 (R1) guidelines for 
parameters like linearity, range, precision, LOD, LOQ, accuracy, 
recovery and stability of the analyte. 
Linearity and range 
The linearity of the analytical method was its ability to elicit test results 
which are directly proportional to analyte concentration in samples 
within a given range. The range was determined to know the interval 
between the upper and lower concentrations of analyte (pure lafutidine) 
that had been demonstrated to determine that the analytical method 
with a suitable level of precision, accuracy and linearity [11]. 
To establish the linearity and range of the proposed method, various 
aliquot portions of 0.5-3 ml of lafutidine stock solution (100µg/ml) 
was separately transferred into 10.0 ml volumetric flask and diluted 
up to the mark with mobile phase (0.1 N HCl, pH 1.20) to obtain final 
concentrations of 5-30 µg/ml respectively. The absorbance at each 
concentration was measured against solvent 0.1 N HCl, pH 1.20 as 
blank at a wavelength of 290 nm. A calibration curve was 
constructed by plotting absorbance of lafutidine (nm) on Y-axis and 
concentration of lafutidine (µg/ml) on X-axis and regression 
equation was calculated for the drug. 
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Precision 
Precision studies were carried out to ascertain the reproducibility of 
results for the proposed method and used to find out intra and 
interday variations in the test method of lafutidine. It was 
determined by repeatability [12]. Repeatability determined by 
preparing six replicates of the same concentration of the sample and 
the absorbance was measured. Intraday precision study was carried 
out by preparing drug solution of same concentrations (5, 10 and 15 
µg/ml) and analysed it at three different times in a day. The same 
procedure was followed for three other days to determine interday 
precision. The results were reported as % RSD. 
Limit of detection (LOD) and limit of quantification (LOQ) 
LOD is the lowest amount of analyte in the study or test sample that 
can be detected. LOQ is the lowest amount of analyte in the study or 
test sample that can be quantitatively determined by suitable 
precision and accuracy [13]. LOD and LOQ were determined by 
using the following equations designated by ICH guidelines.  
LOD–3.3 s/m-----Eq. 1 
LOQ–10 s/m-----Eq. 2 
Wheres is the standard deviation of the response and m is the slope 
of the related calibration curve [14]. 
Accuracy study 
Accuracy study was carried out to assure the closeness of the test 
results obtained by the analytical method to the true value [15]. For 
study methods, samples were prepared in triplicate at three 
different concentrations i.e.10 μg/ml,15 μg/ml and 20 μg/ml within 
the Beer’s law limits and the absorbance of each concentration was 
recorded in triplicate (n=3). The results were reported as SD and % 
RSD. 
Recovery study 
Recovery study was carried out to find the accuracy of the proposed 
method by addition of standard drug solution to a pre-analyzed 
tablet dosage form of lafutidine sample solution at three different 
concentration levels (80 %, 100 % and 120%) within the specified 
linearity and range. The basic concentration level of sample solution 
selected for spiking of the drug 
Standard solution was 10 μg/ml of lafutidine for the used method. 
The % recovery by proposed method was calculated by using the 
formula as given below. 
% Recovery= [(E-T)/P] ×100 
E: Total amount of drug estimated (μg/ml) after standard addition 
T: Amount of drug found in pre-analyzed tablet dosage form (μg/ml) 
P: Amount of pure drug added (μg/ml) 
Robustness 
Robustness was carried out by analyzing-lafutidine concentration on 
different days by different analysts. This study was used to predict 
the effect of various parameters such as different laboratories, 
different analysts, interday and intraday variations [16-17]. 
Assay of marketed formulations of lafutidine 
The average weight of twenty tablets of a marketed brand of 
lafutidine was accurately calculated and these tablets were crushed 
well into a uniform powder. Calculated weight of powdered drug 
was taken to prepare 100 μg/ml stock solution. Three replicates of 
the test solution of 10 μg/ml were prepared from dilution of stock 
solution and sonicated. The amounts of lafutidine were calculated by 
extrapolating the absorbance from the calibration plot. Results of the 
analysis are reported in table 7. 
RESULTS AND DISCUSSION 
Linearity and range 
The absorbance of lafutidine at each concentration of 5-30 µg/ml was 
measured against solvent 0.1 N HCl, pH 1.20 as blank at a wavelength 
of 290 nm. A calibration curve was constructed by plotting absorbance 
versus concentrations and a regression equation was calculated for 
drug. The equation of calibration curve for lafutidine obtained was y = 
0.005+0.019x, Good linearity was observed over the concentration 
range evaluated (5-30 μg/ml) with regression coefficient (r2
 
)=0.9997 
are shown in table 1 and fig. 3. The calibration curve was found to be 
linear for the proposed spectrophotometric method in the 
aforementioned concentrations (5-30 µg/ml). The linear regression 
data for the calibration plot are indicative of a good linear relationship 
between peak area and concentration over a wide range. 
Table 2: Various parameters of developed methods of lafutidine 
Parameter Result 
Absorption Maxima 290 nm 
Beers law Range 0-30 µg/ml 
Correlation Coefficient 0.9994 
Regression Coefficient 0.9997 
Regression Equation Y= 0.005+0.019X 
Slope 0.0191 
Intercept 0.0050 
Standard deviation (SD) 0.00316 
LOD, µg/ml 0.545 
LOQ, µg/ml 1.654 
 
Precision  
In the intraday study, the concentration of drug was calculated 
on the same day at an interval of two hour. In the interday study, 
the concentration of drug contents was calculated on three 
different days within laboratory variation. In both intraday and 
interday precision, study was expressed as relative standard 
deviations (RSD) of a set of results. The precision of the method 
(% RSD) of lafutidine for intraday and interday was found to be 
less than 1% in each concentration showing good repeatability. 
The values of % RSD for both intraday and interday precision are 
shown in table 3. 
 
Table 3: Determination of intraday and interday precision for three different concentrations of lafutidine 
S. No. Normal concentration (µg/ml) Intraday precision (n=3)* Interday precision (n=3)* 
Concentration measured (µg/ml)  
[mean±SD] 
 % RSD Concentration measured (µg/ml)  
[mean±SD] 
% RSD 
1 5 4.97±0.015 0.31 4.95±0.30 0.62 
2 10 9.96±0.025 0.25 9.97±0.025 0.25 
3 15 15.01±0.025 0.17 14.98±0.055 0.37 
*All values are expressed as mean±SD, n=3 
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Limit of detection (LOD) and limit of quantification (LOQ) 
The limit of detection and limit of quantification of lafutidine by 
proposed method was determined using standard deviation method 
with calibration standards. The LCD and LOQ of the proposed 
method were found to be 0.545 µg/ml and 1.654 µg/ml respectively 
indicating that the method developed is sensitive and without the 
interference of the excipients.  
Accuracy study 
Recovery study 
The accuracy of the method was determined and results of the study 
showed a low value of % RSD indicating an accurate method (table 
4) as well as non-interference with the excipients of the formulation. 
To perform the accuracy of the developed method and to study the 
interference of formulation additives, analytical recovery experiments 
were carried out by standard addition method. All value come under 
100±1 % (table 5) that indicate method is accurate. 
Robustness 
Robustness study showed the non-significant difference in the 
amount of drug recovery (% assay) in different laboratory, analyst 
and variations condition. Robustness study suggested that 
developed method was independent in different parameters of 
environmental conditions. 
 
Table 4: Accuracy data for three different concentrations of lafutidine for the developed method 
S. No. Concentration (µg/ml) Absorbance measured (mean±SD) (n=3)* % RSD 
1 10 0.204±0.0015 0.75 
2 15 0.288±0.0020 0.72 
3 20 0.387±0.0020 0.54 
*All values are expressed as mean±SD, n=3 
 
Table 5: Result of recovery study 
Marketed dosage form 
by percentage recovery method 
Content of drug (mg) Level of addition (%) % recovery (n=3)*±% RSD  % mean recovery±% RSD 
 
Lafudac 10 mg 
tablet 
10 80 99.62±0.47  
99.45±0.20 10 100 99.51±0.25 
10 120 99.23±0.54  
Laciloc 10 mg 
tablet 
10 80 99.44±0.75 99.25±0.17 
10 100 99.18±0.58 
10 120 99.13±0.82 
*All values are expressed as mean, n=3 
 
Table 6: Data for robustness study for the developed method 
S. No. Variable parameter Assay result (%) (n=3)* 
1 Analyst 1 99.7 
Analyst 2 99.7 
Analyst 3 99.8 
2 Day 1 99.7 
Day 2 99.6 
Day 3 99.6 
*All values are expressed as mean, n=3 
 
Table 7: Assay of marketed dosage form of lafutidine 
Marketed dosage form Label claim (mg) Amount found (mg) (n=3)* % Purity ±% RSD  
Lafudac 10 mg Tablet 10 9.94 99.40±0.45 
Laciloc 10 mg Tablet 10 9.92 99.20±0.68 
*All values are expressed as mean, n=3 
 
Assay of marketed formulations of lafutidine 
The assay results (% purity) of 20 tablets of different marketed 
brands (Lafudac and Laciloc) were found to be 99.40 %±0.45 and 
99.20 %±0.68 respectively. The estimated content (% purity) was in 
good agreement with the label claims. 
CONCLUSION 
A UV-Spectrophotometric method was developed and validated as 
per the ICH guidelines for lafutidine determination in bulk and 
pharmaceutical dosage form. The solvent (0.1 N HCl, pH 1.20) used 
for this study was inexpensive, appropriate and simple to prepare. 
The developed analytical method was found to be simple, sensitive, 
rapid, economical, linear, reproducible, robust and applicable over a 
wide concentration range with high interday, intraday precision and 
accuracy. The results of the validated parameters were found to be 
satisfactory and can also be applied for the quality control tool in the 
estimation of lafutidine in pharmaceutical dosage forms. The method 
was found suitable to determine the concentration of lafutidine as 
API as well as in dosage form analysis precisely and accurately. The 
sample recovery from the formulation by using this method was 
very applicable in respect to its label claim. 
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